Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
December 11, 2022 10:00 ET
|
Harpoon Therapeutics
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed...
CURE Media Group announces D.L. Hughley as keynote panel moderator for the 2022 Multiple Myeloma Heroes and Health Equity Heroes awards
December 05, 2022 13:38 ET
|
CURE Media Group
CRANBURY, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
December 01, 2022 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE...
CURE Media Group announces 2022 Multiple Myeloma Heroes®
November 17, 2022 09:00 ET
|
CURE Media Group
CRANBURY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
Scip & Savor for a Cure Fundraiser Benefits the International Myeloma Foundation (IMF) and Family Reach
October 27, 2022 08:45 ET
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the recent fundraising celebration hosted by Fatima Scipione and her...
The Annual Miracles for Myeloma 5K Hybrid Run/Walk Celebrates 10th Anniversary
September 29, 2022 08:45 ET
|
International Myeloma Foundation
CLARK, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- The Annual Miracles for Myeloma 5K Hybrid Run/Walk will be celebrating its tenth anniversary this year. For the past nine years, this annual event has...
CURE Media Group Opens Nominations for Multiple Myeloma Heroes® Award Program
August 04, 2022 15:54 ET
|
CURE Media Group
The Recognition Will Honor Individuals Who Have Made a Significant Difference in the Lives of Those Affected by Multiple Myeloma CRANBURY, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CURE Media...
Moving Mountains for Multiple Myeloma® Tackles Mt. Washington
July 01, 2022 09:03 ET
|
CURE Media Group
CRANBURY, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Moving Mountains for Multiple Myeloma®, a program with the mission of raising funds and awareness for multiple myeloma research, will take the...
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 18:12 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
May 05, 2022 16:05 ET
|
Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...